Open AccessBacterial infections in COVID-19 patients and their possible treatments. A review
Author(s) -
A’liyatur Rosyidah,
Mohamad Padri,
Paulus Damar Bayu Murti
Publication year - 2021
Publication title -
berkala penelitian hayati (journal of biological researchers)/berkala penelitian hayati
Language(s) - English
Resource type - Journals
eISSN - 2337-389X
pISSN - 0852-6834
DOI - 10.23869/bphjbr.27.1.20212
Subject(s) - covid-19 , antimicrobial , pandemic , antibiotics , medicine , intensive care medicine , antibiotic resistance , bacterial pneumonia , immunology , microbiology and biotechnology , virology , biology , infectious disease (medical specialty) , outbreak , disease
The COVID-19 pandemic, which started in the beginning of 2020 was triggered by a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, severely affected various sectors, especially health. The effect of COVID-19 on patients is exacerbated by bacterial co-infections and secondary bacterial infections. There are few studies on how bacterial co-infections and secondary bacterial infections worsen COVID-19 patients, including in Indonesia. Therefore, it is necessary to update and summarize the understanding of bacterial infections characteristics to help optimize the diagnosis, prevention, and treatment decisions. Antibiotics have been used in COVID-19 patients to treat bacterial infections to date, which could contribute to antimicrobial resistance in the future. The review s objective is to summarize bacterial infections in COVID-19 patients and several possible treatments, including antibiotics, phage therapy, probiotics/prebiotics, and nanomedicine for antimicrobial peptides (AMPs) delivery